Fatty liver breakthrough? drug that boosts growth hormone shows promise
NCT ID NCT03375788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called tesamorelin in 51 obese adults with nonalcoholic fatty liver disease (NAFLD). The drug is designed to increase growth hormone levels, which may help reduce liver fat and inflammation. Researchers measured changes in liver fat using special scans and biopsies to see if the treatment could improve liver health.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?